Informations: Ceci n’est pas la version la plus récente du modèle de données. Vous trouverez un aperçu de la version à gauche, sous Versions. Vous trouverez la version la plus actuelle ici.
Informations:
Erreur:
ID
26844
Description
Lapatinib Resistance in Patients With Breast Cancer; ODM derived from: https://clinicaltrials.gov/show/NCT00898573
Lien
https://clinicaltrials.gov/show/NCT00898573
Mots-clés
Versions (2)
- 25/10/2017 25/10/2017 -
- 20/09/2021 20/09/2021 -
Détendeur de droits
See clinicaltrials.gov
Téléchargé le
25 octobre 2017
DOI
Pour une demande vous connecter.
Licence
Creative Commons BY 4.0
Modèle Commentaires :
Ici, vous pouvez faire des commentaires sur le modèle. À partir des bulles de texte, vous pouvez laisser des commentaires spécifiques sur les groupes Item et les Item.
Groupe Item commentaires pour :
Item commentaires pour :
Vous devez être connecté pour pouvoir télécharger des formulaires. Veuillez vous connecter ou s’inscrire gratuitement.
Eligibility Breast Cancer NCT00898573
Eligibility Breast Cancer NCT00898573
- StudyEvent: Eligibility
Similar models
Eligibility Breast Cancer NCT00898573
- StudyEvent: Eligibility
Name
Type
Description | Question | Decode (Coded Value)
Type de données
Alias
Invasive carcinoma of breast
Item
pathologically confirmed invasive breast cancer
boolean
C0853879 (UMLS CUI [1])
Disease HER2/Neu Positive
Item
erbb2-positive disease
boolean
C0012634 (UMLS CUI [1,1])
C2348909 (UMLS CUI [1,2])
C2348909 (UMLS CUI [1,2])
lapatinib ditosylate
Item
has received or is currently receiving lapatinib ditosylate
boolean
C1504917 (UMLS CUI [1])
lapatinib ditosylate | Benefit Clinical | Stable Disease | Response Radiography
Item
documented clinical benefit while receiving lapatinib ditosylate (e.g., stable disease of ≥ 12 weeks duration or a radiographic response)
boolean
C1504917 (UMLS CUI [1])
C0814225 (UMLS CUI [2,1])
C0205210 (UMLS CUI [2,2])
C0677946 (UMLS CUI [3])
C1704632 (UMLS CUI [4,1])
C0034571 (UMLS CUI [4,2])
C0814225 (UMLS CUI [2,1])
C0205210 (UMLS CUI [2,2])
C0677946 (UMLS CUI [3])
C1704632 (UMLS CUI [4,1])
C0034571 (UMLS CUI [4,2])
Tumor tissue sample Available Research study
Item
must have tumor tissue samples available for research studies
boolean
C0475358 (UMLS CUI [1,1])
C0470187 (UMLS CUI [1,2])
C0681814 (UMLS CUI [1,3])
C0470187 (UMLS CUI [1,2])
C0681814 (UMLS CUI [1,3])
Hormone Receptor Status Unspecified
Item
hormone receptor status not specified
boolean
C0019929 (UMLS CUI [1,1])
C0449438 (UMLS CUI [1,2])
C0205370 (UMLS CUI [1,3])
C0449438 (UMLS CUI [1,2])
C0205370 (UMLS CUI [1,3])
Client Characteristics
Item
patient characteristics:
boolean
C0815172 (UMLS CUI [1])
Menopausal Status Unspecified
Item
menopausal status not specified
boolean
C1513126 (UMLS CUI [1,1])
C0205370 (UMLS CUI [1,2])
C0205370 (UMLS CUI [1,2])
Pregnancy Absent
Item
not pregnant*
boolean
C0032961 (UMLS CUI [1,1])
C0332197 (UMLS CUI [1,2])
C0332197 (UMLS CUI [1,2])
Coagulation profile Normal
Item
coagulation profile normal*
boolean
C0005790 (UMLS CUI [1,1])
C0205307 (UMLS CUI [1,2])
C0205307 (UMLS CUI [1,2])
Platelet Count measurement | Biopsy post treatment Patient need for
Item
platelet count > 100,000/mm³* note: *for patients requiring a post-treatment biopsy
boolean
C0032181 (UMLS CUI [1])
C0005558 (UMLS CUI [2,1])
C2709088 (UMLS CUI [2,2])
C0686904 (UMLS CUI [2,3])
C0005558 (UMLS CUI [2,1])
C2709088 (UMLS CUI [2,2])
C0686904 (UMLS CUI [2,3])
Therapeutic procedure
Item
prior concurrent therapy:
boolean
C0087111 (UMLS CUI [1])
ID.13
Item
see disease characteristics
boolean
Chemotherapy | trastuzumab | Herceptin
Item
concurrent chemotherapy or trastuzumab (herceptin®) allowed
boolean
C0392920 (UMLS CUI [1])
C0728747 (UMLS CUI [2])
C0338204 (UMLS CUI [3])
C0728747 (UMLS CUI [2])
C0338204 (UMLS CUI [3])
Exclusion Criteria | Anticoagulants | Warfarin | Heparin, Low-Molecular-Weight
Item
no concurrent anticoagulants, including warfarin or low-molecular weight heparin*
boolean
C0680251 (UMLS CUI [1])
C0003280 (UMLS CUI [2])
C0043031 (UMLS CUI [3])
C0019139 (UMLS CUI [4])
C0003280 (UMLS CUI [2])
C0043031 (UMLS CUI [3])
C0019139 (UMLS CUI [4])
Exclusion Criteria | Antiplatelet therapy | Aspirin | clopidogrel | Antiplatelet Agents | Biopsy post treatment Patient need for
Item
no concurrent antiplatelet therapy, including aspirin, clopidogrel, or other antiplatelet agents* note: *for patients requiring a post-treatment biopsy
boolean
C0680251 (UMLS CUI [1])
C1096021 (UMLS CUI [2])
C0004057 (UMLS CUI [3])
C0070166 (UMLS CUI [4])
C0085826 (UMLS CUI [5])
C0005558 (UMLS CUI [6,1])
C2709088 (UMLS CUI [6,2])
C0686904 (UMLS CUI [6,3])
C1096021 (UMLS CUI [2])
C0004057 (UMLS CUI [3])
C0070166 (UMLS CUI [4])
C0085826 (UMLS CUI [5])
C0005558 (UMLS CUI [6,1])
C2709088 (UMLS CUI [6,2])
C0686904 (UMLS CUI [6,3])